阿奇霉素治疗小儿支原体肺炎患儿的临床疗效

Clinical efficacy of azithromycin in the treatment of children with mycoplasma pneumonia

目的研究阿奇霉素治疗小儿支原体肺炎患儿的临床疗效与价值。方法 80例小儿支原体肺炎患儿,采用双盲法分为对照组及实验组,每组40例。对照组接受常规对症治疗,实验组在常规对症治疗基础上联用阿奇霉素治疗。对比两组患儿的治疗效果、炎症指标水平、血气指标、症状缓解时间以及不良反应发生率。结果实验组治疗后C反应蛋白(CRP)水平(3.2±1.5)mg/L低于对照组的(5.9±2.9)mg/L,差异有统计学意义(P<0.05)。实验组治疗后二氧化碳分压(41.3±4.1)mm Hg(1 mm Hg=0.133 kPa)低于对照组的(50.7±6.1)mm Hg,氧分压(83.7±7.2)mm Hg高于对照组的(73.2±10.4)mm Hg,差异有统计学意义(P<0.05)。实验组住院时间、咳嗽消失时间、体温恢复正常时间、肺部啰音消失时间短于对照组,差异有统计学意义(P<0.05)。两组不良反应发生率比较差异无统计学意义(P<0.05)。实验组治疗总有效率100.0%高于对照组的87.5%,差异有统计学意义(P<0.05)。结论针对小儿支原体肺炎患儿,在常规对症治疗基础上联合使用阿奇霉素治疗能够显著改善患儿的炎症情况及血气指标,帮助缩短患儿恢复时间,提高治疗总有效率,同时用药安全性较高,不易导致患儿发生严重用药反应,相较于单纯常规对症治疗效果更好,有推广使用的价值。

Objective To study the clinical efficacy and value of azithromycin in the treatment of children with mycoplasma pneumonia. Methods A total of 80 children with mycoplasma pneumonia were divided into control group and experimental group by double-blind method, with 40 cases in each group. The control group received conventional symptomatic treatment, and the experimental group was treated with azithromycin in combination with conventional symptomatic treatment. The therapeutic effect, inflammation index level, blood gas index, symptom relief time and the incidence of adverse reactions were compared between the two groups.Results After treatment, the C-reactive protein(CRP)(3.2±1.5) mg/L of the experimental group was lower than(5.9±2.9) mg/L of the control group, and the difference was statistically significant(P<0.05). After treatment,the partial pressure of carbon dioxide(41.3±4.1) mm Hg(1 mm Hg=0.133 kPa) of the experimental group was lower than(50.7±6.1) mm Hg of the control group, and the partial pressure of oxygen(83.7±7.2) mm Hg was higher than(73.2±10.4) mm Hg of the control group. All the differences were statistically significant(P<0.05). The hospitalization time, cough disappearance time, body temperature return to normal time, and lung rale disappearance time in the experimental group were shorter than those in the control group, and the difference was statistically significant(P<0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups(P<0.05). The total effective rate 100.0% in the experimental group was higher than 87.5% in the control group, and the difference was statistically significant(P<0.05). Conclusion In the treatment of children with mycoplasma pneumonia, the combination of azithromycin on the basis of conventional symptomatic treatment can significantly improve the inflammation and blood gas index of the children, shorten the recovery time of the children and improve the efficiency of treatment, and at the same time, the drug is safer and less likely to cause serious drug reactions in the children. It contains the value of promotion and application.